Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: August 29th 2022 | Updated: December 5th 2024
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
Published: July 15th 2022 | Updated: December 5th 2024
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
Published: January 6th 2023 | Updated: December 5th 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: November 13th 2024 | Updated: December 5th 2024
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Published: December 1st 2024 | Updated: December 5th 2024
The Targeted Pulse: Unlock Recent FDA Highlights in Leukemia and Prostate Cancer and An Interesting Vaccine Gaining Traction in Triple-Negative Breast Cancer